123 related articles for article (PubMed ID: 11772450)
1. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
2. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
Liang JF; Li YT; Connell ME; Yang VC
AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
[TBL] [Abstract][Full Text] [Related]
4. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
Liang JF; Song H; Li YT; Yang VC
J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
6. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.
Park YJ; Liang JF; Song H; Li YT; Naik S; Yang VC
Adv Drug Deliv Rev; 2003 Feb; 55(2):251-65. PubMed ID: 12564979
[TBL] [Abstract][Full Text] [Related]
7. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
8. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
10. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Absar S; Choi S; Yang VC; Kwon YM
J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
[TBL] [Abstract][Full Text] [Related]
11. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery.
Huang Y; Park YS; Wang J; Moon C; Kwon YM; Chung HS; Park YJ; Yang VC
Curr Pharm Des; 2010 Jul; 16(21):2369-76. PubMed ID: 20618157
[TBL] [Abstract][Full Text] [Related]
12. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
Ye J; Shin MC; Liang Q; He H; Yang VC
J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
[TBL] [Abstract][Full Text] [Related]
13. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator.
Klegerman ME; Zou Y; McPherson DD
J Liposome Res; 2008; 18(2):95-112. PubMed ID: 18569446
[TBL] [Abstract][Full Text] [Related]
14. The ATTEMPTS delivery systems for macromolecular drugs.
Kwon YM; Li Y; Naik S; Liang JF; Huang Y; Park YJ; Yang VC
Expert Opin Drug Deliv; 2008 Nov; 5(11):1255-66. PubMed ID: 18976135
[TBL] [Abstract][Full Text] [Related]
15. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Absar S; Kwon YM; Ahsan F
J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
[TBL] [Abstract][Full Text] [Related]
16. Delivery system for targeted thrombolysis without the risk of hemorrhage.
Byun Y; Yang VC
ASAIO J; 1998; 44(5):M638-41. PubMed ID: 9804513
[TBL] [Abstract][Full Text] [Related]
17. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
18. Enhanced control of bioactivity of tissue plasminogen activator (tPA) through domain-directed enzymatic oxidation of terminal galactose.
Mahdi WA; Absar MS; Choi S; Yang VC; Kwon YM
Bioimpacts; 2022; 12(6):479-486. PubMed ID: 36644546
[No Abstract] [Full Text] [Related]
19. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
[TBL] [Abstract][Full Text] [Related]
20. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP; Gibson CM; McCabe CH; Adgey AA; Schweiger MJ; Sequeira RF; Grollier G; Giugliano RP; Frey M; Mueller HS; Steingart RM; Weaver WD; Van de Werf F; Braunwald E
Circulation; 1998 Dec 22-29; 98(25):2805-14. PubMed ID: 9860780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
